Safety and Efficacy of a Totally Subcutaneous Implantable-Cardioverter Defibrillator

Background— The most frequent complications associated with implantable cardioverter-defibrillators (ICDs) involve the transvenous leads. A subcutaneous implantable cardioverter-defibrillator (S-ICD) has been developed as an alternative system. This study evaluated the safety and effectiveness of the S-ICD System (Cameron Health/Boston Scientific) for the treatment of life-threatening ventricular arrhythmias (ventricular tachycardia/ventricular fibrillation). Methods and Results— This prospective, nonrandomized, multicenter trial included adult patients with a standard indication for an ICD, who neither required pacing nor had documented pace-terminable ventricular tachycardia. The primary safety end point was the 180-day S-ICD System complication-free rate compared with a prespecified performance goal of 79%. The primary effectiveness end point was the induced ventricular fibrillation conversion rate compared with a prespecified performance goal of 88%, with success defined as 2 consecutive ventricular fibrillation conversions of 4 attempts. Detection and conversion of spontaneous episodes were also evaluated. Device implantation was attempted in 321 of 330 enrolled patients, and 314 patients underwent successful implantation. The cohort was followed for a mean duration of 11 months. The study population was 74% male with a mean age of 52±16 years and mean left ventricular ejection fraction of 36±16%. A previous transvenous ICD had been implanted in 13%. Both primary end points were met: The 180-day system complication-free rate was 99%, and sensitivity analysis of the acute ventricular fibrillation conversion rate was >90% in the entire cohort. There were 38 discrete spontaneous episodes of ventricular tachycardia/ventricular fibrillation recorded in 21 patients (6.7%), all of which successfully converted. Forty-one patients (13.1%) received an inappropriate shock. Conclusions— The findings support the efficacy and safety of the S-ICD System for the treatment of life-threatening ventricular arrhythmias. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01064076.

[1]  P. Heidenreich,et al.  Long-Term Outcome After ICD and CRT Implantation and Influence of Remote Device Follow-Up: The ALTITUDE Survival Study , 2010, Circulation.

[2]  V L Gott,et al.  Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. , 1980, The New England journal of medicine.

[3]  K. Anstrom,et al.  Long-term Follow-up in the Sudden Cardiac Death Heart Failure Trial (SCD-HEFT) , 2012 .

[4]  Wojciech Zareba,et al.  Reduction in inappropriate therapy and mortality through ICD programming. , 2012, The New England journal of medicine.

[5]  C. Ervin,et al.  Lead extraction in the contemporary setting: the LExICon study: an observational retrospective study of consecutive laser lead extractions. , 2010, Journal of the American College of Cardiology.

[6]  Analysis of electrocardiograms for subcutaneous monitors. , 2003, Journal of electrocardiology.

[7]  R. Tieleman,et al.  Is Surface ECG a Useful Surrogate for Subcutaneous ECG? , 2010, Pacing and clinical electrophysiology : PACE.

[8]  L. Eckardt,et al.  Shock efficacy of the subcutaneous ICD for prevention of sudden cardiac death: Initial multicenter experience , 2013 .

[9]  G. Mairesse,et al.  The usefulness of surface 12-lead electrocardiogram to predict intra-atrial conduction block after successful atrial flutter ablation. , 2003, Journal of electrocardiology.

[10]  B. Wilkoff,et al.  How to treat and identify device infections. , 2007, Heart rhythm.

[11]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[12]  Alexander H Maass,et al.  An entirely subcutaneous implantable cardioverter-defibrillator. , 2010, The New England journal of medicine.

[13]  S. Shkurovich,et al.  Implantable cardioverter-defibrillator prescription in the elderly. , 2009, Heart rhythm.

[14]  C. Israel,et al.  Electrical Storm in Patients with an Implanted Defibrillator: A Matter of Definition , 2007, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[15]  Thomas Kleemann,et al.  Annual Rate of Transvenous Defibrillation Lead Defects in Implantable Cardioverter-Defibrillators Over a Period of >10 Years , 2007, Circulation.

[16]  M. Keller,et al.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. , 1997, The New England journal of medicine.

[17]  N Engl,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. , 1997, Circulation.

[18]  Stephen L Moore,et al.  Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. , 2008, Journal of the American College of Cardiology.

[19]  B. Wilkoff,et al.  Differences in Tachyarrhythmia Detection and Implantable Cardioverter Defibrillator Therapy by Primary or Secondary Prevention Indication in Cardiac Resynchronization Therapy Patients , 2004, Journal of cardiovascular electrophysiology.

[20]  D. Cohen,et al.  The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. , 2006, Journal of the American College of Cardiology.

[21]  M. Gold,et al.  Head‐To‐Head Comparison of Arrhythmia Discrimination Performance of Subcutaneous and Transvenous ICD Arrhythmia Detection Algorithms: The START Study , 2012, Journal of cardiovascular electrophysiology.

[22]  W. Grimm,et al.  Complications of Implantable Cardioverter Defibrillator Therapy in 440 Consecutive Patients , 2005, Pacing and clinical electrophysiology : PACE.

[23]  Claudia Stöllberger,et al.  Guidelines for device-based therapy of cardiac rhythm abnormalities. , 2009, Heart rhythm.

[24]  A. Moss,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. , 1996, The New England journal of medicine.

[25]  G. Boriani,et al.  A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: the RELEVANT [Role of long dEtection wind , 2009, European heart journal.

[26]  S. Saba,et al.  Recent Trends in Utilization of Implantable Cardioverter‐Defibrillators in Survivors of Cardiac Arrest in the United States , 2009, Pacing and clinical electrophysiology : PACE.

[27]  M. Hannan,et al.  Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices. , 2012, JAMA.

[28]  D. Mark,et al.  Prognostic importance of defibrillator shocks in patients with heart failure. , 2008, The New England journal of medicine.

[29]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[30]  Jeroen J. Bax,et al.  Risk of Failure of Transvenous Implantable Cardioverter-Defibrillator Leads , 2008, Circulation. Arrhythmia and electrophysiology.

[31]  Harlan M Krumholz,et al.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker , 2008, Circulation.

[32]  David L Hayes,et al.  Clinical Predictors of Cardiovascular Implantable Electronic Device‐Related Infective Endocarditis , 2009, Pacing and clinical electrophysiology : PACE.

[33]  M. Rosenqvist,et al.  Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study. European 7219 Jewel ICD investigators. , 1998, Circulation.